Table 3.
Current clinical trials analyzing the safety and efficacy of combinations treatments with small molecule inhibitors or radium 223
| Clinical Trial | Primary Anticancer Agent | Secondary Anticancer Agent | Phase | Current Status | Estimated Completion Date |
|---|---|---|---|---|---|
| NCT03840200 | Ipatasertib (AKT inhibitor) | Rucaparib (PARP inhibitor) | I/II | Recruiting | November 5, 2021 |
| NCT03874884 | Olaparib | 177Lu-PSMA-617 | II | Recruiting | October 2022 |
| TRAP (NCT03787680) | Olaparib | AZD6738 (ATM Inhibitor) | II | Recruiting | November 2025 |
| NCT02893917 | Olaparib | Cediranib (Anti-angiogenesis) | II | Active, not recruiting | December 2020 |
| NCT03810105 | Olaparib | Durvalumab | II | Recruiting | February 2021 |
| NCT03574571 | Radium 223 | Docetaxel | III | Recruiting | June 2023 |
| NCT03737370 | Radium 223 | Docetaxel | II | Recruiting | October 31, 2021 |
| PEACE III (NCT02194842) | Radium 223 | Enzalutamide | III | Recruiting | December 2025 |
| NCT02225704 | Radium 223 | Enzalutamide | II | Active, not recruiting | December 2022 |
| NCT04019327 | Talazoparib (PARP Inhibitor) | Temozolomide | I/II | Recruiting | July 2022 |
| NCT02711956 | ZEN003696 (BETi) | Enzalutamide | I/II | Active, not recruiting | October 2019 |
| NCT04471974 | ZEN003696 | Enzalutamide, Pembrolizuman | II | Not yet recruiting | August 31, 2025 |
Other various small molecule or Radium 223 combinations have emerged due to the fact that not many anti-cancer agents can effectively suppress CRPC for less than a year. PARP inhibitors have becoming an area of major interest as they have been shown to be quite effective in patients with mutations in DNA repair pathways.